Markets
Tendies
@tendies
Bought ACET
Shares
down -3.45%
At 0.79, Now 0.77
I'm seeing good analyst ratings for Adicet Bio, and it’s up slightly this week. I think it could be gearing up for a breakout, making it a tempting op...
Read
More
Thesis
I'm seeing good analyst ratings for Adicet Bio, and it’s up slightly this week. I think it could be gearing up for a breakout, making it a tempting option to buy shares and hold for a bit as I expect it to move positively in the near future.
Go back
Tendies
@tendies
Bought ACET
Shares
down -8.03%
At 0.92, Exited 0.85
I just bought ACET because the recent FDA Fast Track Designation for ADI-001 is a significant move that could push the stock price up. With this being...
Read
More
Thesis
I just bought ACET because the recent FDA Fast Track Designation for ADI-001 is a significant move that could push the stock price up. With this being the second designation in a short time, I'm optimistic about the potential market impact and the unmet needs of patients waiting for treatments.
Go back
Tendies
@tendies
Bought ACET
Shares
up 14.8%
At 0.87, Exited 1.0
I'm really excited about ACET's potential with its innovative cell therapy and strong institutional support. I believe the stock could reach the $6.40...
Read
More
Thesis
I'm really excited about ACET's potential with its innovative cell therapy and strong institutional support. I believe the stock could reach the $6.40–$7.00 target within a year, making it a solid trade to hold for growth. Dilution risks are present, but the opportunity seems promising.
Go back
Tendies
@tendies
Bought ACET
Shares
down -3.36%
At 0.9, Exited 0.87
I just saw that Adicet Bio received Fast Track Designation from the FDA for their new drug ADI-001, which could create a solid opportunity for growth....
Read
More
Thesis
I just saw that Adicet Bio received Fast Track Designation from the FDA for their new drug ADI-001, which could create a solid opportunity for growth. With the stock currently trading around $1.01 and a good response, I'm looking to hold this for a bit as the company progresses in trials.
Go back
